Does the media favor ANIX or XFOR?

In the previous week, Anixa Biosciences had 1 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 3 mentions for Anixa Biosciences and 2 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 1.45 beat Anixa Biosciences' score of 1.29 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive X4 Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, DMAC or ANIX?

Anixa Biosciences is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DiaMedica Therapeutics N/A N/A -$32.77M -$0.71 N/A Anixa Biosciences N/A N/A -$10.93M -$0.31 N/A

Is DMAC or ANIX more profitable?

Anixa Biosciences' return on equity of -71.12% beat DiaMedica Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets DiaMedica Therapeutics N/A -77.15% -69.23% Anixa Biosciences N/A -71.12% -62.88%

Does the media refer more to UPB or ANIX?

In the previous week, Upstream Bio had 1 more articles in the media than Anixa Biosciences. MarketBeat recorded 4 mentions for Upstream Bio and 3 mentions for Anixa Biosciences. Upstream Bio's average media sentiment score of 1.80 beat Anixa Biosciences' score of 1.29 indicating that Upstream Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upstream Bio 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Anixa Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ANIX or KMDA more profitable?

Kamada has a net margin of 11.21% compared to Anixa Biosciences' net margin of 0.00%. Kamada's return on equity of 7.73% beat Anixa Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Anixa Biosciences N/A -71.12% -62.88% Kamada 11.21% 7.73% 5.41%

Does the media prefer ANIX or KMDA?

In the previous week, Kamada had 2 more articles in the media than Anixa Biosciences. MarketBeat recorded 5 mentions for Kamada and 3 mentions for Anixa Biosciences. Anixa Biosciences' average media sentiment score of 1.29 beat Kamada's score of 0.67 indicating that Anixa Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kamada 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ANIX or PBYI?

Anixa Biosciences currently has a consensus price target of $8.50, indicating a potential upside of 129.73%. Given Anixa Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Anixa Biosciences is more favorable than Puma Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anixa Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer ANIX or PBYI?

In the previous week, Anixa Biosciences had 1 more articles in the media than Puma Biotechnology. MarketBeat recorded 3 mentions for Anixa Biosciences and 2 mentions for Puma Biotechnology. Anixa Biosciences' average media sentiment score of 1.29 beat Puma Biotechnology's score of 0.94 indicating that Anixa Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Puma Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Anixa Biosciences (ANIX) Competitors

$3.70 -0.05 (-1.33%)

As of 07/24/2026 04:00 PM Eastern

Compare

ANIX vs. XFOR, DMAC, UPB, KMDA, and PBYI

Should you buy Anixa Biosciences stock or one of its competitors? MarketBeat compares Anixa Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anixa Biosciences include X4 Pharmaceuticals (XFOR), DiaMedica Therapeutics (DMAC), Upstream Bio (UPB), Kamada (KMDA), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry.

How does Anixa Biosciences compare to X4 Pharmaceuticals?

Anixa Biosciences (NASDAQ:ANIX) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Anixa Biosciences presently has a consensus price target of $8.50, suggesting a potential upside of 129.73%. X4 Pharmaceuticals has a consensus price target of $9.70, suggesting a potential upside of 151.95%. Given X4 Pharmaceuticals' higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Anixa Biosciences had 1 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 3 mentions for Anixa Biosciences and 2 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 1.45 beat Anixa Biosciences' score of 1.29 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
X4 Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anixa Biosciences has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by company insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Anixa Biosciences has higher earnings, but lower revenue than X4 Pharmaceuticals. Anixa Biosciences is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	N/A	N/A	-$10.93M	-$0.31	N/A
X4 Pharmaceuticals	$35.11M	10.34	-$79.20M	-$4.54	N/A

Anixa Biosciences has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. Anixa Biosciences' return on equity of -71.12% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%

Summary

Anixa Biosciences beats X4 Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Anixa Biosciences compare to DiaMedica Therapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

In the previous week, Anixa Biosciences had 2 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for Anixa Biosciences and 1 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.87 beat Anixa Biosciences' score of 1.29 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
DiaMedica Therapeutics	Very Positive
Anixa Biosciences	Positive

DiaMedica Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 78.04%. Anixa Biosciences has a consensus target price of $8.50, indicating a potential upside of 129.73%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Anixa Biosciences is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Anixa Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by insiders. Comparatively, 26.4% of Anixa Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

DiaMedica Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

Anixa Biosciences' return on equity of -71.12% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.15%	-69.23%
Anixa Biosciences	N/A	-71.12%	-62.88%

Anixa Biosciences is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A
Anixa Biosciences	N/A	N/A	-$10.93M	-$0.31	N/A

Summary

Anixa Biosciences beats DiaMedica Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Anixa Biosciences compare to Upstream Bio?

Upstream Bio (NASDAQ:UPB) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Anixa Biosciences has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -43.82% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,718.96%	-43.82%	-42.27%
Anixa Biosciences	N/A	-71.12%	-62.88%

Upstream Bio has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

Upstream Bio currently has a consensus price target of $33.17, indicating a potential upside of 417.42%. Anixa Biosciences has a consensus price target of $8.50, indicating a potential upside of 129.73%. Given Upstream Bio's higher probable upside, analysts clearly believe Upstream Bio is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Anixa Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Upstream Bio had 1 more articles in the media than Anixa Biosciences. MarketBeat recorded 4 mentions for Upstream Bio and 3 mentions for Anixa Biosciences. Upstream Bio's average media sentiment score of 1.80 beat Anixa Biosciences' score of 1.29 indicating that Upstream Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upstream Bio	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Anixa Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

29.1% of Anixa Biosciences shares are held by institutional investors. 16.5% of Upstream Bio shares are held by company insiders. Comparatively, 26.4% of Anixa Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Anixa Biosciences has lower revenue, but higher earnings than Upstream Bio. Anixa Biosciences is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$3.32M	105.01	-$143.44M	-$2.91	N/A
Anixa Biosciences	N/A	N/A	-$10.93M	-$0.31	N/A

Summary

Upstream Bio beats Anixa Biosciences on 9 of the 16 factors compared between the two stocks.

How does Anixa Biosciences compare to Kamada?

Anixa Biosciences (NASDAQ:ANIX) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

Kamada has higher revenue and earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	N/A	N/A	-$10.93M	-$0.31	N/A
Kamada	$180.46M	2.25	$20.20M	$0.35	20.17

Anixa Biosciences has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, Kamada has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

Anixa Biosciences presently has a consensus target price of $8.50, suggesting a potential upside of 129.73%. Kamada has a consensus target price of $13.00, suggesting a potential upside of 84.14%. Given Anixa Biosciences' higher probable upside, equities research analysts plainly believe Anixa Biosciences is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Kamada has a net margin of 11.21% compared to Anixa Biosciences' net margin of 0.00%. Kamada's return on equity of 7.73% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Kamada	11.21%	7.73%	5.41%

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by company insiders. Comparatively, 36.1% of Kamada shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Kamada had 2 more articles in the media than Anixa Biosciences. MarketBeat recorded 5 mentions for Kamada and 3 mentions for Anixa Biosciences. Anixa Biosciences' average media sentiment score of 1.29 beat Kamada's score of 0.67 indicating that Anixa Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kamada	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kamada beats Anixa Biosciences on 11 of the 15 factors compared between the two stocks.

How does Anixa Biosciences compare to Puma Biotechnology?

Anixa Biosciences (NASDAQ:ANIX) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Puma Biotechnology has a net margin of 10.69% compared to Anixa Biosciences' net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Puma Biotechnology	10.69%	20.30%	12.05%

Puma Biotechnology has higher revenue and earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	N/A	N/A	-$10.93M	-$0.31	N/A
Puma Biotechnology	$228.40M	1.78	$31.11M	$0.48	16.63

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Anixa Biosciences had 1 more articles in the media than Puma Biotechnology. MarketBeat recorded 3 mentions for Anixa Biosciences and 2 mentions for Puma Biotechnology. Anixa Biosciences' average media sentiment score of 1.29 beat Puma Biotechnology's score of 0.94 indicating that Anixa Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Puma Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anixa Biosciences has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

Anixa Biosciences currently has a consensus price target of $8.50, indicating a potential upside of 129.73%. Given Anixa Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Anixa Biosciences is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Puma Biotechnology beats Anixa Biosciences on 9 of the 16 factors compared between the two stocks.

Get Anixa Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIX vs. The Competition

Export

Metric	Anixa Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$127.59M	$3.67B	$6.86B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-11.94	21.48	27.14	23.64
Price / Sales	N/A	169.92	517.01	89.03
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	8.81	7.88	10.28	6.07
Net Income	-$10.93M	$23.86M	$3.60B	$331.99M
7 Day Performance	8.82%	-3.82%	-1.27%	-0.63%
1 Month Performance	41.22%	-2.61%	-0.37%	-2.00%
1 Year Performance	14.91%	32.79%	18.30%	13.62%

Anixa Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIX Anixa Biosciences	4.4616 of 5 stars	$3.70 -1.3%	$8.50 +129.7%	+9.8%	$127.59M	N/A	N/A	5	Positive News Analyst Upgrade
XFOR X4 Pharmaceuticals	2.8776 of 5 stars	$4.05 -8.2%	$9.70 +139.5%	+110.4%	$415.95M	$35.11M	N/A	80	News Coverage Positive News
DMAC DiaMedica Therapeutics	1.7056 of 5 stars	$7.49 -2.3%	$12.33 +64.7%	+38.1%	$413.29M	N/A	N/A	20
UPB Upstream Bio	3.1589 of 5 stars	$7.28 -3.3%	$33.17 +355.6%	-52.0%	$409.78M	$2.85M	N/A	38	News Coverage
KMDA Kamada	4.9621 of 5 stars	$7.17 +0.7%	$12.00 +67.4%	-9.3%	$409.44M	$180.46M	20.49	360	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anixa Biosciences (ANIX) Competitors

ANIX vs. XFOR, DMAC, UPB, KMDA, and PBYI

How does Anixa Biosciences compare to X4 Pharmaceuticals?

Summary

How does Anixa Biosciences compare to DiaMedica Therapeutics?

Summary

How does Anixa Biosciences compare to Upstream Bio?

Summary

How does Anixa Biosciences compare to Kamada?

Summary

How does Anixa Biosciences compare to Puma Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIX vs. The Competition

Anixa Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anixa Biosciences (ANIX) Competitors

ANIX vs. XFOR, DMAC, UPB, KMDA, and PBYI

How does Anixa Biosciences compare to X4 Pharmaceuticals?

Do analysts recommend ANIX or XFOR?

Does the media favor ANIX or XFOR?

Which has more volatility and risk, ANIX or XFOR?

Do insiders and institutionals have more ownership in ANIX or XFOR?

Which has better valuation & earnings, ANIX or XFOR?

Is ANIX or XFOR more profitable?

Summary

How does Anixa Biosciences compare to DiaMedica Therapeutics?

Does the media refer more to DMAC or ANIX?

Do analysts rate DMAC or ANIX?

Do institutionals & insiders believe in DMAC or ANIX?

Which has more volatility & risk, DMAC or ANIX?

Is DMAC or ANIX more profitable?

Which has preferable earnings and valuation, DMAC or ANIX?

Summary

How does Anixa Biosciences compare to Upstream Bio?

Is UPB or ANIX more profitable?

Which has more risk & volatility, UPB or ANIX?

Do analysts prefer UPB or ANIX?

Does the media refer more to UPB or ANIX?

Do insiders & institutionals believe in UPB or ANIX?

Which has better valuation and earnings, UPB or ANIX?

Summary

How does Anixa Biosciences compare to Kamada?

Which has stronger valuation & earnings, ANIX or KMDA?

Which has more volatility and risk, ANIX or KMDA?

Do analysts rate ANIX or KMDA?

Is ANIX or KMDA more profitable?

Do insiders and institutionals hold more shares of ANIX or KMDA?

Does the media prefer ANIX or KMDA?

Summary

How does Anixa Biosciences compare to Puma Biotechnology?

Is ANIX or PBYI more profitable?

Which has stronger valuation and earnings, ANIX or PBYI?

Do institutionals & insiders believe in ANIX or PBYI?

Does the media prefer ANIX or PBYI?

Which has more risk & volatility, ANIX or PBYI?

Do analysts rate ANIX or PBYI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIX vs. The Competition

Anixa Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools